Organophosphates and Nerve Agents: Atropine, Pralidoxime and Ageing

One enzyme, and what happens when it stops

Acetylcholine is meant to be a flash, not a flood. Every time a nerve signals through acetylcholine, an enzyme called acetylcholinesterase (AChE) waits at the synapse to chop the transmitter apart within milliseconds, ending the signal cleanly. This is the whole housekeeping of cholinergic transmission covered in the Autonomic Nervous System chapter — acetylcholine acts, cholinesterase clears it, the receptor resets. Organophosphates (and their cousins the carbamates) do one thing: they inhibit AChE. Bind the enzyme, and the acetylcholine is never cleared. It piles up and keeps hammering every cholinergic receptor in the body, over and over. The poison never touches a receptor itself — it simply removes the off-switch, and the body's own transmitter does the damage.

Because acetylcholine is a transmitter at several very different sites, one blocked enzyme produces a chaotic, multi-front attack. It floods the muscarinic receptors of the parasympathetic organs (glands, gut, airways, heart), the nicotinic receptors of skeletal muscle and autonomic ganglia, and the cholinergic synapses of the brain. Each site gives its own set of signs, and the deadly ones and the dramatic ones are not the same. Learning the toxidrome means keeping those three fronts separate in your head.

The muscarinic front: the killer is fluid, not the twitch

The classic mnemonics list secretions everywhere — but only some of them kill. Muscarinic overstimulation is the flood of the parasympathetic "rest and digest" system taken to a lethal extreme. Students memorize it as SLUDGE (Salivation, Lacrimation, Urination, Defecation, Gastrointestinal cramps, Emesis) or DUMBELS. But the signs that actually kill are captured better by the "killer Bs": Bronchorrhoea (the airways literally fill with secretions), Bronchospasm, and Bradycardia. A patient does not die from wetting themselves or crying — they die because their lungs fill with fluid and their heart slows. Add the pupils: pinpoint miosis is a hallmark, and unlike the anticholinergic toxidrome of the neighbouring chapter, the skin here is wet, not dry. That contrast — wet cholinergic versus dry anticholinergic — is one of the cleanest discriminators in all of toxicology.

The nicotinic and CNS fronts

The nicotinic front looks paradoxical, because nicotinic receptors sit on skeletal muscle and on autonomic ganglia (both sympathetic and parasympathetic). Overstimulate muscle end-plates and you first get fasciculations — those fine, rippling twitches — then weakness, and finally a depolarizing paralysis that can stop the diaphragm. At the ganglia the sympathetic side can win out, so despite all the muscarinic bradycardia a patient may show tachycardia, hypertension and dilated pupils. That is why heart rate and pupil size are unreliable single guides — the two systems are fighting. The CNS front is simpler to state and just as dangerous: acetylcholine floods the brain, producing agitation, confusion, seizures and, ultimately, coma with respiratory depression. Seizures here are managed exactly as in the Central Nervous System chapter — with benzodiazepines, which are also neuroprotective in nerve-agent exposure.

Diagnosis: the nose and the toxidrome first

Diagnosis is clinical and should not wait for a laboratory. The combination of pinpoint pupils, streaming secretions, wet lungs, fasciculations and a depressed conscious level — the cholinergic toxidrome laid out in the Toxidromes chapter — is enough to start treatment. A garlicky or solvent-like odour on the breath or clothes is a classic bedside clue. Confirmation, when it comes, is by measuring cholinesterase activity: red-cell (true) acetylcholinesterase reflects the synaptic enzyme most faithfully, while plasma (butyryl) cholinesterase falls earlier and is easier to assay but less specific. These levels help confirm the diagnosis and track recovery, but crucially they are too slow to guide the first, life-saving minutes. You treat the patient in front of you, not the pending result.

Management, part one: protect yourself, then the airway

The first person an organophosphate can poison after the patient is the person treating them. Before any antidote, two things happen in parallel. First, decontamination with staff protection: the patient's skin, hair and clothes carry the poison, and rescuers have themselves been poisoned by handling contaminated patients — this is secondary contamination. Remove the clothing, wash the skin, and wear gloves, gown and eye protection. With volatile nerve agents this becomes a full hazmat problem. Second, aggressive airway and secretion control: because bronchorrhoea and bronchospasm are what kill, high-flow oxygen, suction and a secured airway come before almost everything else. Only then — often simultaneously — do the antidotes begin.

The antidotes: atropine dries, pralidoxime reactivates

Two antidotes, two completely different jobs — and only one of them races the clock. Atropine is a muscarinic antagonist. It does nothing to the enzyme and nothing for the nicotinic fasciculations or paralysis — it simply blocks the muscarinic receptors so the flood of acetylcholine can no longer reach them (the same antagonism taught with the cholinergic system in the Autonomic Nervous System chapter). Its purpose is to dry the secretions and open the airways: you titrate to a clear chest and drying secretions, NOT to the pupils and NOT to a target heart rate. This is the single most-tested management point in the whole topic. Because the receptors are being hammered continuously, the doses required are often enormous — repeated, escalating, sometimes hundreds of milligrams over a day, far beyond any ordinary use. Under-atropinisation, chasing the pupils instead of the lungs, is a classic and fatal error.

The second antidote fixes what atropine cannot. An oxime — pralidoxime (2-PAM) or obidoxime — attacks the root cause: it reactivates acetylcholinesterase. The oxime binds the organophosphate that is stuck on the enzyme and pulls the phosphate group off, freeing the enzyme to work again. Because it restores the enzyme itself, it is the only agent that helps the nicotinic problems — the fasciculations, the weakness, the paralysis atropine can't touch. But there is a deadline. Over time the enzyme-poison bond undergoes ageing: a chemical group is lost and the phosphate becomes covalently, irreversibly locked to the enzyme. After ageing, no oxime can ever prise it off — the only recovery left is the body synthesizing brand-new enzyme over days to weeks. The ageing time depends on the agent: slow (many hours) for many pesticides, but frighteningly fast for some nerve agents — soman ages in only a couple of minutes, which is why pre-treatment and instant therapy matter in chemical-warfare exposure. The lesson is blunt: give the oxime early, before ageing, or don't bother.

Two later surprises: intermediate syndrome and delayed neuropathy

The acute crisis is not always the end. A day or several days after apparent recovery from the cholinergic phase, some patients develop the intermediate syndrome: a proximal muscle and respiratory weakness, thought to reflect ongoing nicotinic dysfunction, that can silently cause respiratory failure — a reason these patients are watched closely even after they look better. Separately, weeks later, certain organophosphates cause organophosphate-induced delayed polyneuropathy (OPIDN): a distal sensorimotor neuropathy driven by a different enzyme target (neuropathy target esterase), which the antidotes do not prevent or treat. Neither is part of the immediate cholinergic emergency, but both explain why an organophosphate poisoning is a story told over weeks, not hours.